Search clinical trials for: KESIMPTA

Total 23 results

Novartis Pharmaceuticals

Not yet recruiting

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Multiple Sclerosis, Relapsing-Remitting
Novartis Pharmaceuticals

Recruiting

A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice (CRONOS-MS)

Relapsing Forms of Multiple Sclerosis

Spain
Novartis Pharmaceuticals

Not yet recruiting

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

Multiple Sclerosis
Novartis Pharmaceuticals

Recruiting

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France (SEPROS)

Multiple Sclerosis (MS)

France
Novartis Pharmaceuticals

Recruiting

WOE of Anti-CD20 Therapies

Multiple Sclerosis

United States
Novartis Pharmaceuticals

Recruiting

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

Relapsing Multiple Sclerosis

Portugal
Novartis Pharmaceuticals

Recruiting

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years (KRONOS)

Relapsing Multiple Sclerosis

Austria
Novartis Pharmaceuticals

Recruiting

Kesimpta (Ofatumumab) Pregnancy Registry

Multiple Sclerosis | Pregnancy

United States
Guy's and St Thomas' NHS Foundation Trust

Not yet recruiting

Intra-articular Injection of Lidocaine in Inflammatory Arthritis

Inflammatory Arthritis
Novartis Pharmaceuticals

Recruiting

Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS)

Multiple Sclerosis

Switzerland
University of Southern California
Novartis Pharmaceuticals

Recruiting

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

Relapsing Remitting Multiple Sclerosis

United States
National Institute of Allergy and Infectious Diseases...
PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN); Blood...

Recruiting

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

Relapsing Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Johns Hopkins University
Patient-Centered Outcomes Research Institute; National Multiple Sclerosis Society

Recruiting

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)

Multiple Sclerosis, Relapsing-Remitting

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Recurrent Adult Lymphoblastic Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
Novartis Pharmaceuticals

Active, not recruiting

Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies (KAIROS)

Multiple Sclerosis

Germany
Novartis Pharmaceuticals

Active, not recruiting

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

Relapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple Sclerosis

Japan
The Cleveland Clinic
University of Nottingham

Active, not recruiting

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom
Novartis Pharmaceuticals

Completed

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

Multiple Sclerosis

United States
Johns Hopkins University
Novartis

Enrolling by invitation

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Multiple Sclerosis | Retinal Degeneration | Visual Acuity | Tomography, Optical Coherence

United States
University of Nebraska
GlaxoSmithKline; Celgene Corporation

Completed

Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Burkitt Lymphoma | AIDS-Related Burkitt Lymphoma | Atypical Burkitt/Burkitt-Like Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2... and other conditions

United States
Novartis Pharmaceuticals

Completed

The 'Wearing Off' Effect of DMT

Multiple Sclerosis

Switzerland

Search clinical trials for: KESIMPTA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations